Compare American Financial Group Inc (AFG) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs BioNTech SE - ADR — how do they compare? American Financial Group Inc trades at $144.75 (market cap $11.97B), while BioNTech SE - ADR trades at $93.17 (market cap $23.31B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and American Financial Group Inc pays a 2.44% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AFG | BNTX | |
|---|---|---|
Market Cap | $11.97B | $23.31B |
Sector | Financials | Health |
52-Week High | $148.71 | $119.34 |
52-Week Low | $124.18 | $83.89 |
Enterprise Value | $12.35B | $6.60B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.77, down 0.76% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 59. The stock shows consistent profitability with a net income margin of 11.66% and ROE of 20.41%, though revenue dipped slightly in 2025. Recent Q2 2026 earnings beat estimates, driven by strong P&C underwriting and investment income, as reported by Business Wire on August 4, 2026.
The outlook remains positive with a consensus price target of $160.67, implying 12.5% upside. Risks include potential earnings volatility and competitive pressures in the insurance sector. Analyst sentiment is mixed with 41% buy ratings, but no sell recommendations, supporting a cautiously optimistic view for long-term investors.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
